Assignee
CELGENE CORP
US·478 granted patents·251 pending applications·14,082 citations·filing 1983–2025
Top patents by PatentIndex Score
729 records- 0199US9101622B2Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasoneCELGENE CORP·Filed 2014·Granted Aug 11, 2015·60 cites·25 claims
- 0299US9101621B2Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantationCELGENE CORP·Filed 2014·Granted Aug 11, 2015·744 cites·21 claims
- 0399US8735428B2Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dioneCELGENE CORP·Filed 2013·Granted May 27, 2014·37 cites·27 claims
- 0499US8673939B2Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dioneCELGENE CORP·Filed 2013·Granted Mar 18, 2014·41 cites·35 claims
- 0599US7893101B2Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereofCELGENE CORP·Filed 2008·Granted Feb 22, 2011·44 cites·15 claims
- 0699US7468363B2Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2005·Granted Dec 23, 2008·79 cites·24 claims
- 0799US7393862B2Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemiasCELGENE CORP·Filed 2005·Granted Jul 1, 2008·100 cites·25 claims
- 0899US6555554B2Isoindolines, method of use, and pharmaceutical compositionsCELGENE CORP·Filed 2001·Granted Apr 29, 2003·245 cites·17 claims
- 0999US6476052B1Isoindolines, method of use, and pharmaceutical compositionsCELGENE CORP·Filed 2000·Granted Nov 5, 2002·295 cites·28 claims
- 1099US6335349B1Substituted 2(2,6-dioxopiperidin-3-yl)isoindolinesCELGENE CORP·Filed 2000·Granted Jan 1, 2002·301 cites·23 claims
- 1199US6316471B1Isoindolines, method of use, and pharmaceutical compositionsCELGENE CORP·Filed 2000·Granted Nov 13, 2001·334 cites·26 claims
- 1299US6281230B1Isoindolines, method of use, and pharmaceutical compositionsCELGENE CORP·Filed 2000·Granted Aug 28, 2001·400 cites·26 claims
- 1399US5929117AImmunotherapeutic agentsCELGENE CORP·Filed 1997·Granted Jul 27, 1999·319 cites·11 claims
- 1499US5877200ACyclic amidesCELGENE CORP·Filed 1997·Granted Mar 2, 1999·351 cites·33 claims
- 1599US5874448ASubstituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levelsCELGENE CORP·Filed 1997·Granted Feb 23, 1999·285 cites·23 claims
- 1699US5798368ATetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levelsCELGENE CORP·Filed 1996·Granted Aug 25, 1998·305 cites·8 claims
- 1799US5698579ACyclic amidesCELGENE CORP·Filed 1996·Granted Dec 16, 1997·345 cites·35 claims
- 1898US8530498B1Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2013·Granted Sep 10, 2013·32 cites·13 claims
- 1998US7968569B2Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2003·Granted Jun 28, 2011·87 cites·15 claims
- 2098US7874984B2Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drugCELGENE CORP·Filed 2005·Granted Jan 25, 2011·111 cites·4 claims
- 2198US7863297B2Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromesCELGENE CORP·Filed 2007·Granted Jan 4, 2011·41 cites·17 claims
- 2298US7855217B2Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2008·Granted Dec 21, 2010·42 cites·10 claims
- 2398US7635700B25-Substituted quinazolinone derivatives and compositions comprising and methods of using the sameCELGENE CORP·Filed 2007·Granted Dec 22, 2009·78 cites·16 claims
- 2498US7465800B2Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2004·Granted Dec 16, 2008·87 cites·14 claims
- 2598US7427638B2(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereofCELGENE CORP·Filed 2005·Granted Sep 23, 2008·53 cites·13 claims
- 2698US7244759B2Isoindoline compounds and methods of making and using the sameCELGENE CORP·Filed 2004·Granted Jul 17, 2007·138 cites·6 claims
- 2798US7189740B2Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromesCELGENE CORP·Filed 2003·Granted Mar 13, 2007·137 cites·34 claims
- 2898US7091353B2Isoindole-imide compounds, compositions, and uses thereofCELGENE CORP·Filed 2001·Granted Aug 15, 2006·147 cites·15 claims
- 2998US6962940B2(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereofCELGENE CORP·Filed 2003·Granted Nov 8, 2005·107 cites·23 claims
- 3098US6395754B1Substituted 2-(2,6-dioxopiperidin-3-yl)- phthalimides and 1-oxoisoindolines and method of reducing TNFα levelsCELGENE CORP·Filed 1998·Granted May 28, 2002·296 cites·12 claims
- 3198US6380239B1Substituted 1-oxo- and 1,3-dioxoisoindoline and method of reducing inflammatory cytokine levelsCELGENE CORP·Filed 2000·Granted Apr 30, 2002·253 cites·18 claims
- 3298US6020358ASubstituted phenethylsulfones and method of reducing TNFα levelsCELGENE CORP·Filed 1998·Granted Feb 1, 2000·296 cites·19 claims
- 3398US5955476ASubstituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levelsCELGENE CORP·Filed 1998·Granted Sep 21, 1999·267 cites·23 claims
- 3498US5605914AImidesCELGENE CORP·Filed 1994·Granted Feb 25, 1997·152 cites·32 claims
- 3597US9499514B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2015·Granted Nov 22, 2016·28 cites·29 claims
- 3697US9056120B2Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidineCELGENE CORP·Filed 2013·Granted Jun 16, 2015·19 cites·53 claims
- 3797US8759375B2Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with proteasome inhibitorCELGENE CORP·Filed 2013·Granted Jun 24, 2014·18 cites·37 claims
- 3897US7659302B2Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dioneCELGENE CORP·Filed 2008·Granted Feb 9, 2010·35 cites·20 claims
- 3997US6528530B2Phenidate drug formulations having diminished abuse potentialCELGENE CORP·Filed 2001·Granted Mar 4, 2003·132 cites·4 claims
- 4097US6355656B1Phenidate drug formulations having diminished abuse potentialCELGENE CORP·Filed 1999·Granted Mar 12, 2002·147 cites·4 claims
- 4197US6315720B1Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drugCELGENE CORP·Filed 2000·Granted Nov 13, 2001·219 cites·32 claims
- 4297US6200987B1Cyclic amidesCELGENE CORP·Filed 2000·Granted Mar 13, 2001·52 cites·16 claims
- 4397US6011050ASubstituted phenethylsulfones and method of reducing TNFα levelsCELGENE CORP·Filed 1999·Granted Jan 4, 2000·172 cites·16 claims
- 4497US5635517AMethod of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolinesCELGENE CORP·Filed 1996·Granted Jun 3, 1997·643 cites·10 claims
- 4596US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 4696US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 4796US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 4896US10047151B2Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictorCELGENE CORP·Filed 2016·Granted Aug 14, 2018·19 cites·5 claims
- 4996US9695146B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2014·Granted Jul 4, 2017·17 cites·43 claims
- 5096US9611465B2Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cellCELGENE CORP·Filed 2015·Granted Apr 4, 2017·29 cites·3 claims
Showing the top 50 of 729 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CELGENE CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →